87 related articles for article (PubMed ID: 29557085)
1. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Inno A; Di Noia V; Martini M; D'Argento E; Di Salvatore M; Arena V; Schinzari G; Orlandi A; Larocca LM; Cassano A; Barone C
Pathol Oncol Res; 2019 Apr; 25(2):513-520. PubMed ID: 29557085
[TBL] [Abstract][Full Text] [Related]
2. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Patel SH; Rimner A; Foster A; Zhang Z; Woo KM; Yu HA; Riely GJ; Wu AJ
Lung Cancer; 2017 Jun; 108():109-114. PubMed ID: 28625621
[TBL] [Abstract][Full Text] [Related]
3. Current Approaches in NSCLC Targeting K-RAS and EGFR.
Aran V; Omerovic J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739412
[TBL] [Abstract][Full Text] [Related]
4. Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer.
Alandağ C; Merev E; Özdemir F
Anticancer Drugs; 2021 Sep; 32(8):882-885. PubMed ID: 34145175
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
Blumenschein GR; Saintigny P; Liu S; Kim ES; Tsao AS; Herbst RS; Alden C; Lee JJ; Tang X; Stewart DJ; Kies MS; Fossella FV; Tran HT; Mao L; Hicks ME; Erasmus J; Gupta S; Girard L; Peyton M; Diao L; Wang J; Davis SE; Minna JD; Wistuba I; Hong WK; Heymach JV; Lippman SM
Clin Cancer Res; 2013 Dec; 19(24):6967-75. PubMed ID: 24166906
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.
Weiss GJ; Ganeshan B; Miles KA; Campbell DH; Cheung PY; Frank S; Korn RL
PLoS One; 2014; 9(7):e100244. PubMed ID: 24987838
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals
De B; Farooqi AS; Mitchell KG; Ludmir EB; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Swisher SG; Gibbons DL; Zhang J; Le X; Elamin YY; Gomez DR; Ning MS; Lin SH; Liao Z; Chang JY; Vaporciyan AA; Heymach JV; Antonoff MB; Gandhi SJ
JCO Precis Oncol; 2023 Jan; 7():e2200540. PubMed ID: 36716413
[TBL] [Abstract][Full Text] [Related]
8. Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis.
Wang Y; Qu X; Shen HC; Wang K; Liu Q; Du JJ
Asian Pac J Cancer Prev; 2015; 16(11):4759-68. PubMed ID: 26107237
[TBL] [Abstract][Full Text] [Related]
9. ReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.
Moecks J; Soulières D; Klughammer B
J Pathol Clin Res; 2015 Jul; 1(3):134-43. PubMed ID: 27499899
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity.
Park YH; Cho S; Yee J; Kim JY; Rhie SJ; Gwak HS
Anticancer Drugs; 2018 Jun; 29(5):471-476. PubMed ID: 29557814
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
Medicine (Baltimore); 2018 Apr; 97(16):e0460. PubMed ID: 29668619
[TBL] [Abstract][Full Text] [Related]
14. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
[TBL] [Abstract][Full Text] [Related]
15. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Wen F; Zheng H; Zhang P; Hutton D; Li Q
BMJ Open; 2018 Apr; 8(4):e020128. PubMed ID: 29654023
[TBL] [Abstract][Full Text] [Related]
16. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Wu YL; Sequist LV; Tan EH; Geater SL; Orlov S; Zhang L; Lee KH; Tsai CM; Kato T; Barrios CH; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin Yang J; Paz-Ares L; Park K
Clin Lung Cancer; 2018 Jul; 19(4):e465-e479. PubMed ID: 29653820
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
Li C; Liu H; Zhang B; Gong L; Su Y; Zhang Z; Wang C
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1079-1086. PubMed ID: 29616327
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Takemura Y; Chihara Y; Morimoto Y; Tanimura K; Imabayashi T; Seko Y; Kaneko Y; Date K; Ueda M; Arimoto T; Iwasaki Y; Takayama K
Anticancer Res; 2018 Apr; 38(4):2385-2390. PubMed ID: 29599365
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
20. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
